79$/KG
Product Detailed Description
liposomal Salicylic Acid 80% is a premium-grade dietary supplement ingredient delivering salicylic acid in an advanced liposomal delivery system. Salicylic acid (CAS 69-72-7), also known as 2-hydroxybenzoic acid or o-hydroxybenzoic acid, is a beta hydroxy acid (BHA) with the molecular formula C₇H₆O₃ and a molecular weight of 138.12 g/mol. It is a white crystalline powder that is poorly soluble in water (0.2% at 20°C) and is characterized by a pKa of 2.9 and a density of 1.44 g/cm³. Salicylic acid is the active metabolite of acetylsalicylic acid (aspirin) and is found naturally in the bark of willow trees and in various fruits and vegetables.
Salicylic acid is a lipophilic compound that penetrates the sebaceous follicles of the skin, where it exerts keratolytic, comedolytic, and anti-inflammatory effects. It works by dissolving the intercellular cement that holds corneocytes together, thereby promoting desquamation and unclogging pores. Salicylic acid has been present in OTC topical acne preparations at concentrations of 2% to 5%, external analgesics, skin protectants, and topical antifungal drugs. It is an approved active ingredient for use in topical OTC acne drug products at concentrations of 0.5% to 2%.
Conventional salicylic acid presents significant formulation challenges. The compound is poorly water-soluble and can cause irritation and stinging at effective concentrations. Following topical application, salicylic acid is rapidly absorbed through the skin, with approximately 15% of the systemic exposure of an oral 81 mg aspirin dose following application of a 2% topical product. This rapid systemic absorption limits its residence time in the target skin layers.
Liposomal encapsulation provides four critical advantages:
1. Enhanced Skin Retention and Reduced Systemic Absorption — Liposomal encapsulation of salicylic acid resulted in a decrease in systemic absorption relative to control formulations and an increase in skin concentration, especially in the stratum corneum and epidermis. This targeted delivery profile maximizes local efficacy while minimizing systemic exposure.
2. Prolonged Tissue Residence Time — A salicylic acid/γ-cyclodextrin (SA/γ-CyD) conjugate entrapped in liposomes demonstrated a higher entrapment ratio than SA alone, with the release of the conjugate from RAW264.7 cells markedly slower compared with free SA. The residence time of the conjugate in tissues was significantly prolonged compared with conventional liposomal systems.
3. Protection from Degradation — The SA/γ-CyD conjugate in solid state was found to be an amorphous powder, and the release of SA from the conjugate in phosphate-buffered saline was tolerant to chemical and enzymatic degradation, demonstrating enhanced stability of the encapsulated form.
4. Sustained Release for Prolonged Activity — Liposomal delivery provides a controlled-release profile that maintains steady levels of salicylic acid at the target site, supporting prolonged keratolytic and sebum-regulating activity rather than a sharp peak followed by rapid clearance.
High Purity — Standardized to ≥80% salicylic acid by HPLC, with typical purity of 99.7–99.9% for premium cosmetic-grade material.
Liposomal Enhancement — Phospholipid bilayer encapsulation achieves decreased systemic absorption and increased skin concentration, especially in the stratum corneum and epidermis.
Prolonged Tissue Residence — SA/γ-CyD conjugate entrapped in liposomes demonstrated a higher entrapment ratio and significantly prolonged residence time in tissues compared with conventional liposomal systems.
Sebum-Regulating and Anti-Acne — Salicylic acid penetrates lipid-rich sebaceous follicles, dissolves intercellular cement, and reduces corneocyte cohesion to unclog pores and reduce acne.
Keratolytic and Skin-Renewing — Promotes desquamation and skin renewal by dissolving the intercellular cement that holds corneocytes together.
Anti-Inflammatory Support — Salicylic acid exhibits anti-inflammatory activity that reduces acne inflammation and redness.
Regulatory Compliant — Salicylic acid is an FDA-approved active ingredient for topical OTC acne drug products at concentrations of 0.5% to 2%. CIR Expert Panel concluded that salicylic acid is "safe as used when formulated to avoid irritation and when formulated to avoid increased sun sensitivity".
Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
| Application | Recommended Usage | Notes |
|---|---|---|
| Capsules / Tablets | 50–100 mg per serving | 1–2 capsules daily with meals |
| Functional Beverages | 25–50 mg per 250 mL | Water-dispersible; suitable for RTD formats |
| Powdered Drink Mixes | 50–200 mg per sachet | Best absorbed when taken with food |
| Sebum Regulation Formulas | 50–100 mg per serving | Often combined with zinc, niacinamide, or green tea extract |
| Skin Renewal Formulas | 50–100 mg per serving | Often combined with vitamin C, collagen, or hyaluronic acid |
| Anti-Acne Formulas | 50–100 mg per serving | Often combined with zinc, vitamin B6, or probiotics |
| Topical Formulations | 0.5–2% in formulation | Compatible with non-ionic emulsifiers; can be compounded with niacinamide, hyaluronic acid, or glycerin |
Clinical studies and regulatory guidelines provide guidance on salicylic acid dosing. For topical OTC acne drug products, salicylic acid is approved at concentrations of 0.5% to 2%. Salicylic acid has been present in OTC topical acne preparations at concentrations of 2% to 5%, external analgesics and skin protectants for poison ivy, oak, and sumac, and topical antifungal drugs. For treating corns, salicylic acid ointment at approximately 5% concentration is applied twice daily, and for antifungal corn treatments, compound salicylic acid liniment at approximately 6% concentration is applied 3–4 times daily. For oral supplementation, 50–200 mg per day is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability and targeted skin delivery.
Important Safety Information: Salicylic acid should not be used by individuals with known hypersensitivity to salicylates or aspirin. The FDA advises that similar precautions be taken for the use of cosmetics containing BHAs: test any product on a small area of skin before applying it to a large area; if skin irritation or prolonged stinging occurs, stop using the product and consult a physician; do not exceed the recommended applications; avoid using BHA-containing products on infants and children; and use sun protection if using a BHA product. Pregnant or lactating women and children should consult a healthcare professional before use. The long-term safety of salicylic acid in cosmetics is being evaluated in studies initiated by FDA and sponsored by the National Toxicology Program.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
Salicylic Acid Encyclopedia — Scientific Background
Salicylic acid (CAS 69-72-7), also known as 2-hydroxybenzoic acid or o-hydroxybenzoic acid, is a beta hydroxy acid (BHA) with the molecular formula C₇H₆O₃ and a molecular weight of 138.12 g/mol. It is a white to cream crystalline powder or needles that is poorly soluble in water (0.2% at 20°C) and is characterized by a pKa of 2.9 and a density of 1.44 g/cm³. Salicylic acid is a lipophilic monohydroxybenzoic acid, a beta-hydroxy acid, and a member of the class of compounds known as phenolic acids.
Salicylic acid is found naturally in the bark of willow trees (Salix species), from which it was first isolated in 1828 by Johann Buchner. The compound is also present in wintergreen leaves, sweet birch, and various fruits and vegetables. Its name derives from the Latin word salix (willow). Historically, willow bark extracts were used by ancient civilizations including the Sumerians, Egyptians, and Greeks for their analgesic and anti-inflammatory properties. In the 19th century, salicylic acid was chemically synthesized, and its acetylated derivative, acetylsalicylic acid (aspirin), was developed by Bayer in 1897.
Salicylic acid is classified as a beta hydroxy acid (BHA) because the hydroxyl group is separated from the carboxyl group by two carbon atoms. This structural feature distinguishes it from alpha hydroxy acids (AHAs), where the hydroxyl group is adjacent to the carboxyl group. From a chemist's perspective, salicylic acid is not a true BHA, but cosmetic companies often refer to it as a BHA. The lipophilic nature of salicylic acid allows it to penetrate lipid-rich sebaceous follicles, making it particularly effective for acne treatment compared to water-soluble AHAs.
Salicylic acid's primary mechanism of action involves the dissolution of the intercellular cement that holds corneocytes together. This reduces corneocyte cohesion and promotes desquamation, thereby unclogging pores and reducing comedone formation. Salicylic acid is lipophilic and penetrates the sebaceous follicles, where it exerts its keratolytic and comedolytic effects. Unlike AHAs, which primarily affect the surface of the skin, salicylic acid penetrates deeper into the pore lining, making it particularly effective for acne and blackhead management.
Salicylic acid exhibits anti-inflammatory activity through inhibition of cyclooxygenase (COX) enzymes and reduction of prostaglandin synthesis. It also modulates the NF-κB signaling pathway, reducing the production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. This anti-inflammatory effect contributes to the reduction of acne-related redness and inflammation.
Salicylic acid helps regulate sebum production and secretion by penetrating the sebaceous glands and reducing sebum accumulation. This helps to minimize the oily appearance of the skin and reduces the formation of comedones.
Liposomal encapsulation of salicylic acid provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the salicylic acid molecule, forming a protective shell that enhances skin retention and reduces systemic absorption. This delivery system:
Achieves decreased systemic absorption and increased skin concentration, especially in the stratum corneum and epidermis
Demonstrates a higher entrapment ratio with SA/γ-CyD conjugate compared with SA alone
Provides a markedly slower release from macrophage cells compared with free SA
Significantly prolongs the residence time of salicylic acid in tissues
A salicylic acid/γ-cyclodextrin conjugate was synthesized and entrapped in liposomes by a freezing-thawing method. The conjugate was found to be an amorphous powder, and the release of SA from the conjugate in phosphate-buffered saline was tolerant to chemical and enzymatic degradation. The particle sizes and stability of the liposomes were almost identical, and the entrapment ratio of the SA/γ-CyD conjugate in liposomes was higher than those of SA alone and the SA/γ-CyD complex. The cellular uptake of these liposomes was almost equivalent, but the release of SA/γ-CyD conjugate from RAW264.7 cells was markedly slower compared with that of SA from cells following cellular uptake of the SA-in-liposome and complex-in-liposome systems. The residence time of the conjugate in tissues was significantly prolonged compared with that of the SA-in-liposome and complex-in-liposome systems.
Salicylic acid is an approved active ingredient for use in topical OTC acne drug products at concentrations of 0.5% to 2%. It has been present in OTC topical acne preparations at concentrations of 2% to 5%. Salicylic acid works by penetrating the sebaceous follicles and dissolving the intercellular cement, reducing corneocyte cohesion and promoting desquamation to unclog pores.
For treating corns, salicylic acid ointment at approximately 5% concentration is applied twice daily, and for antifungal corn treatments, compound salicylic acid liniment at approximately 6% concentration is applied 3–4 times daily.
A study in 38 female volunteers determined the bioavailability of salicylic acid after dermal exposure compared to oral administration. The data indicated that use of a 2% topical product is approximately 15% of that following an oral administration of 81 mg aspirin. Liposomal encapsulation reduces systemic absorption while increasing skin concentration, providing a more favorable safety and efficacy profile.
The antimicrobial efficacy of free salicylic acid and liposomal formulations against Cutibacterium acnes (formerly Propionibacterium acnes) was evaluated using the broth microdilution method according to CLSI recommendations. Liposomal formulations demonstrated enhanced antimicrobial activity compared to free salicylic acid.
Salicylic acid has a well-established safety profile when used appropriately. The Cosmetic Ingredient Review (CIR) Expert Panel reached the tentative conclusion that the use of salicylic acid related substances in cosmetics is "safe as used when formulated to avoid irritation and when formulated to avoid increased sun sensitivity". CIR added that "when sun sensitivity would be expected, directions for use [should] include the daily use of sun protection".
The FDA advises that similar precautions be taken for the use of cosmetics containing BHAs:
Test any product containing a BHA on a small area of skin before applying it to a large area. If skin irritation or prolonged stinging occurs, stop using the product and consult a physician.
Follow the use instructions on the label. Do not exceed the recommended applications.
Avoid using BHA-containing products on infants and children.
The long-term safety of salicylic acid in cosmetics is being evaluated in studies initiated by FDA and sponsored by the National Toxicology Program. These government-sponsored studies are examining the long-term effects of both glycolic acid (an AHA) and salicylic acid on the skin's response to ultraviolet (UV) light.
Regulatory Status:
United States — Salicylic acid is an FDA-approved active ingredient for topical OTC acne drug products at concentrations of 0.5% to 2%. It is also permitted in OTC external analgesics and skin protectants.
European Union — Salicylic acid is regulated as a cosmetic ingredient with specific concentration limits. The SCCS has evaluated its safety profile and established conditions of use.
Global Standards — Salicylic acid is monographed in the USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. The ASEAN method for determination of salicylic acid in cosmetic products by HPLC has been established.
Precautions: Individuals with known hypersensitivity to salicylates or aspirin should avoid salicylic acid supplementation. Salicylic acid should not be used by pregnant or lactating women without medical supervision. Children and adolescents should not use salicylic acid supplements without medical supervision. Salicylic acid may interact with anticoagulant medications and should not be used concurrently without medical supervision.
Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.
This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.
79$/KG
RELATED
RELATED
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）